DGKA and cancer: In addition, two novel DGKα inhibitor compounds, namely 11 and 20 (with an IC50 of 1.6 and 1.8 μM respectively, thus representing the most potent DGKα inhibitors until now), decreased cell migration in cancer cells (Figure 2) [122].